Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Hawaii Pharm LLC
WARNING LETTER
•Hawaii Pharm LLC•November 7, 2019

Hawaii Pharm LLC – FDA Warning Letter, Nov 7, 2019

Record Details

The FDA inspected Hawaii Pharm's facility in Honolulu, HI, from October 30 to November 7, 2019, identifying serious violations of the Federal Food, Drug, and Cosmetic Act and applicable regulations. The firm's dietary supplement products are deemed adulterated under 21 CFR Part 111 (CGMP) due to failures in establishing identity specifications for components, finished product specifications, preparing Master Manufacturing Records (MMRs) and Batch Production Records (BPRs), maintaining written complaint procedures, and collecting reserve samples. Additionally, products containing *Sida cordifolia* (Bala) are adulterated under section 402(f) for presenting an unreasonable risk due to ephedrine alkaloids. Several products are also misbranded under section 403 and 21 CFR Part 101 for lacking a domestic address/phone for adverse event reporting, failing to list other ingredients, non-compliant Supplement Facts labels (e.g., incorrect daily value statements), and not identifying plant parts for botanical ingredients. The firm's November 20, 2019, response was inadequate due to a lack of supporting documentation. The FDA also noted concerns about *Asarum Splendens* (Wild Ginger) as a potential source of aristolochic acid. Hawaii Pharm must take prompt corrective actions and respond within fifteen working days with detailed steps and documentation to prevent recurrence, or face legal action including seizure and injunction.

Company
Hawaii Pharm LLC
Inspection date
November 7, 2019
Product type
Food
Office
Division of Human and Animal Food Operations - West V
Person
  • Darla R. Bracy
View Company Profile

ID · 0822f50b-50c2-4679-9732-3407c4848a8a

Violation Codes10
21 U.S.C. 34321 U.S.C. 343(q)(5)(F)21 CFR 11121 U.S.C. 342(g)(1)21 CFR 111.70(b)(1)21 CFR 111.75(a)(1)(i)21 CFR 111.75(a)(2)21 CFR 111.70(e)21 CFR 111.205(a)21 CFR 111.255(a)

Full citation text and observation details available on the Dashboard.

Other documents for Hawaii Pharm LLC
  • 483 - 2019-11-07November 7, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hawaii Pharm LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.